C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 211/18 (2006.01) A61K 9/00 (2006.01) A61K 31/473 (2006.01) A61K 47/44 (2006.01) A61P 15/00 (2006.01) A61P 25/00 (2006.01) C07D 221/18 (2006.01) C07D 409/12 (2006.01) A61K 47/10 (2006.01) A61K 47/20 (2006.01)
Patent
CA 2419842
New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation of such derivatives are also disclosed.
L'invention concerne de nouveaux dérivés d'aporphine de la formule (I) et leurs sels physiologiquement acceptables. Lesdits dérivatifs peuvent être utilisés pour le traitement de la maladie de Parkinson, l'hémicrânie, le syndrôme des jambes sans repos, les troubles sexuels chez les hommes et les femmes, l'hyperprolactinémie et les troubles psychotiques, et/ou l'évaluation de la maladie de Parkinson. L'invention concerne également des procédés permettant la préparation de tels dérivés.
Andren Per Erik
Cremers Thomas
Dijkstra Durk
Jurva Ulrik
Marchais Sandrine
Axon Biochemicals B.v.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
New aporphine esters and their use in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with New aporphine esters and their use in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New aporphine esters and their use in therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1846933